Indicators of buprenorphine and methadone use and abuse: What do we know?

American Journal on Addictions

Volumn 19, Issue 1, 2010, Pages 73-88

  Maxwell, Jane Carlisle ^a   McCance Katz, Elinore F ^b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; METHADONE;

ADULT; ARTICLE; DEATH; DRUG ABUSE; DRUG INTOXICATION; DRUG MONITORING; DRUG TRAFFIC; FEMALE; HUMAN; MALE; PATIENT EDUCATION; PHYSICIAN; POISON CENTER; PRESCRIPTION;

BUPRENORPHINE; DOSAGE FORMS; DRUG THERAPY, COMBINATION; HEALTH CARE SURVEYS; HEALTH SURVEYS; HUMANS; METHADONE; OPIOID-RELATED DISORDERS; STREET DRUGS;

EID: 77149153726     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/j.1521-0391.2009.00008.x     Document Type: Article

References (62)

1. Hall A, Logan J, Toblin R, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008 300 : 2613 2620.
2. Paulozzi L, Budnitz D, Yongli X. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf 2006 15 : 618 627. (Pubitemid 44404658)
3. Fingerhut LA. Increases in methadone-related deaths: 1999-2004. National Center for Health Statistics. Available at : http://www2d.cdc.gov/ncidod/ts/ print.asp. Accessed March 19, 2009.
4. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Special data runs, Excel-All-sup-1created on April 23, 2009.
5. International Statistical Classification of Diseases and Related Health Problems 10th Revision, Version for 2007. Available at : http://apps.who.int/ classifications/apps/icd/icd10online/. Accessed March 31, 2009.
6. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Data Archive. Available at : http://www.icpsr.umich.edu/cocoon/SAMHDA/ DAS3/00056.xml. Accessed April 29, 2009.
7. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration 2003). Results from the 2002 National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NHSDA Series H-22, DHHS Publication No. SMA 03-3836). Rockville, MD, Table 1.107 A & B.
8. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration 2005). Overview of Findings from the 2004 National Survey on Drug Use and Health (Office of Applied Studies, NSDUH Series H-27, DHHS Publication No. SMA 05-4061). Rockville, MD, Tables 1.129 A and B.
9. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration 2006). Results from the 2005 National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H-30, DHHS Publication No. SMA 06-4194). Rockville, MD, Table 1.28 A&B.
10. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies (2009). Results from the 2008 National Survey on Drug Use and Health: National Findings (NSDUH Series H-36, DHHS Publication No. SMA 09-4343). Rockville, MD, Detailed tables 1.89 A&B.
11. SDI Vector data provided by Covidien, June 8, 2009.
12. RADARS, 2008 human exposure calls, data run April 10, 2009.
13. Texas Department of State Health Services, Texas Poison Center Network, special data run, April 3, 2009.
14. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Special data runs, April 24, 2009.
15. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Special data runs, May 5, 2009.
16. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set (TEDS) Highlights - 2007 National Admissions to Substance Abuse Treatment Services. OAS Series S-45, HHS Publication No. (SMA) 09-4360, Rockville, MD, 2009.
17. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set (TEDS): 1993-2003. National Admissions to Substance Abuse Treatment Services, DASIS Series: S-29, DHHS Publication No. (SMA) 05-4118, Rockville, MD, 2005.
18. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies 2007). Treatment Episode Data Set (TEDS), 1992-2005. Concatenated data [Computer file]. Original data prepared by Synectics for Management Decisions, Incorporated. ICPSR ed. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [producer and distributor]. Data downloaded on April 15, 2008.
19. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. National Survey of Substance Abuse Treatment Services (N-SSATS) : 2007. Data on Substance Abuse Treatment Facilities, DASIS Series: S-44, DHHS Publication No. (SMA) 08-4348, Rockville, MD, 2008.
20. Warner M, Chen LH, Makuc DM. Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006. NCHS data brief, no 22. Hyattsville, MD : National Center for Health Statistics. 2009.
21. Warner M, Fingerhut L, Chen Li-H. Methadone deaths, 1999-2005, Findings from the National Vital Statistics System, National Center for Health Statistics, PowerPoint presentation dated November 2008.
22. RADARS System Poison Center Methadone Mortality Data, April 14, 2009.
23. Maxwell J. Poster, Increases in Methadone-Related Adverse Events. Is it pills or liquid? American Conference on Pain Medicine, New York City, April 2008.
24. U.S. Department of Justice, Drug Enforcement Administration, NFLIS 25 Most Frequently Identified Substances, data downloaded May 15, 2009.
25. U.S. Department of Justice, Drug Enforcement Administration, Special data runs, April 29, 2009 and May 9, 2009.
26. McNicholas L. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction: A treatment improvement protocol (TIP 40). Rockville, MD : U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment, 2004.
27. Jones H, Johnson R, Jasinski D, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: Effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005 79 : 1 10.
28. Alho H, Sinclair D, Vuori E, et al. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007 103 : 25 29.
29. Obadia Y, Perrin V, Feroni I, et al. Injecting misuse of buprenorphine among French drug users. Addiction. 2001 96 : 267 272.
30. Sporer K. Buprenorphine: A primer for emergency physicians. Ann Emergency Med 2004 43 : 580 584.
31. United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. National Survey on Drug Use and Health, 2006 [Computer file]. ICPSR21240-v4. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2009-08-12. doi:10.3886/ICPSR21240.
32. Colliver J, Kroutil L, Dai L, et al 2006). Misuse of prescription drugs: Data from the 2002, 2003, and 2004 National Surveys on Drug Use and Health (DHHS Publication No. SMA 06-4192, Analytic Series A-28). Rockville, MD : Substance Abuse and Mental Health Services Administration, Office of Applied Studies.
33. Iguchi M, Handelsman L, Bickel W, et al. Benzodiazepine and sedative use/abuse by methadone maintenance clients. Drug Alcohol Depend. 1993 32 : 257 266.
34. Nielsen S, Dietz P, Lee N, et al. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. Addiction. 2007 102 : 616 622.
35. Thirion X, Lapierre V, Micallef J, et al. Buprenorphine prescription by general practitioners in a French region. Drug and Alcohol Dependence. 2002 65 : 197 204.
36. Lavie E, Fatséas M, Denis C, et al. Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: Correlates of use, abuse and dependence. Drug Alcohol Depend. 2009 99 : 338 344.
37. Ross J, Teesson M, Darke S, et al. The characteristics of heroin users entering treatment: Findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev. 2005 24 : 411 418. (Pubitemid 43024040)
38. Peles E, Schreiber S, Adelson M. Variables associated with perceived sleep disorders in methadone maintenance treatment (MMT) patients. Drug Alcohol Depend. 2006 82 : 103 110.
39. Lintzeris N, Nielsen S. Benzodiazepines, methadone and buprenorphine: Interactions and clinical management. Am J Addict. DOI : 10.1111/j.1521-0391. 2009.00007.x.
40. Trescot A, Datta S, Lee M, et al. Opioid pharmacology. Pain Physician. 2008 11 (2 Suppl S133 S153.
41. Nutt D, Malizia A. New insights into the role of the GABAA-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry 2001 179 : 390 396.
42. Preston K, Griffiths R, Cone E, et al. Diazepam and methadone blood levels following concurrent administration of diazepam and methadone. Drug Alcohol Depend. 1986 18 : 192 202.
43. Nielsen S, Dietze P, Lee N, et al. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. Addiction. 2007 102 : 616 622.
44. Mégarbane B, Hreiche R, Pirnay S, et al. Does high-dose buprenorphine cause respiratory depression? Possible mechanisms and therapeutic consequences. Toxicol Rev. 2006 25 : 79 85.
45. Flockhart D. (2007). Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine. Available at : http://medicine.iupui.edu/flockhart/table.htm. Accessed August 31, 2009.
46. Ferrari A, Coccia C, Bertolini A, et al. Methadone: Metabolism, pharmacokinetics, and interactions. Pharmacol Res 2004 50 : 551 559.
47. Gerber J, Rosenkranz S, Segal Y, et al. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: Results of AIDS Clinical Trials Group (ACTG) 401. J Acquir Immune Defic Syndr. 2001 27 : 153 160.
48. Flockhart D. (2007). Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine. Available at : http://medicine.iupui.edu/flockhart/table.htm. Accessed August 31, 2009.
49. Krantz M, Kutinsky I, Robertson A, et al. Dose-related effects of methadone on QT prolongation in a series of patients with torsades de pointes. Pharmacotherapy. 2003 23 : 802 805.
50. Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clin Pharmacol Ther. 1994 55 : 569 580.
51. Flockhart D. (2007). Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine. Available at : http://medicine.iupui.edu/flockhart/table.htm. Accessed August 31, 2009.
52. Bornstein S, Skopp G. An in vitro approach to potential methadone metabolic-inhibition interactions. Eur J Clin Pharmacol. 2007 63 : 821 827.
53. Waters B, Kaustubh G. Intravenous Quetiapine-Cocaine Use ("Q-Ball"). Am J Psychiatry. 2007 164 : 173 174.
54. Uehlinger C, Crettol S, Chassot P, et al. Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients. J Clin Psychopharmacol. 2007 27 : 273 278.
55. Physician's Desk Reference 2007). Prescribing information: Zyprexa (olanzepine). 61 : 1830 1838.
56. Physician's Desk Reference 2007). Prescribing information: Risperdal (risperidone). 61 : 1676 1682.
57. Vandel P, Talon JM, Haffen E, et al. Pharmacogenetics and drug therapy in psychiatry-the role of the CYP2D6 polymorphism. Curr Pharmaceutical Design 2007 13 : 241 250.
58. Shah N, Lathrop S, Landen M. Unintentional methadone-related overdose death in New Mexico (USA) and implications for surveillance, 1998-2002. Addiction 2005 100 : 176 188.
59. Graham N, Merlo L, Goldberger B, et al. Methadone- and heroin-related deaths in Florida. Am J Drug Alcohol Abuse. 2008 34 : 347 353.
60. Sims S, Snow L, Porucznik C. Surveillance of methadone-related adverse drug events using multiple public health data sources. J Biomed Inform 2007 40 : 382 289.
61. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment 2007). Summary Report of the: Methadone Mortality Meeting - A Reassessment, Available at : http://dpt.samhsa.gov/pdf/Methadone-Report-10%2018%2007-Brief%20w%20attch. pdf. Accessed June 8, 2009.
62. FDA Amendments Act of 2007 (FDAAA).